labetuzumab-SN-38 immunoconjugate IMMU-130

{
  "id": "MLC-T-ONC-014684",
  "term": "labetuzumab-SN-38 immunoconjugate IMMU-130",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) containing labetuzumab, a mildly reduced, anti-CEACAM5 humanized monoclonal antibody, conjugated to the potent topoisomerase I inhibitor SN-38, with antineoplastic activity. The monoclonal antibody moiety of antibody-drug conjugate IMMU-130 selectively binds to carcinoembryonic cell adhesion molecule 5 (CEACAM5), which is abundantly expressed on the surface of a majority of solid tumors. Upon internalization and proteolytic cleavage, SN-38, the active metabolite of irinotecan, inhibits the activity of topoisomerase I in the tumor cells, eventually inhibiting both DNA replication and transcription and leading to tumor cell apoptosis.",
  "abbreviation": "ADC IMMU-130",
  "synonyms": [
    "hMN14-SN38"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/labetuzumab-sn-38-immunoconjugate-immu-130/"
}